Advances in Immunotherapy for Cancer Treatment: Targeting the Immune System to Fight Tumors

Dr. Nishant Sharma; Dr. Pranav Sharma; Dr. Tushar Vashist; Dr. Ankita Saroha*

doi:10.36676/jrps.v15.i2.1592

Authors

Dr. Nishant Sharma Dialysis Medical Officer, Civil Hospital, Palwal
Dr. Pranav Sharma Intern, N.C Medical College and Hospital, Panipat
Dr. Tushar Vashist Junior Resident, Pathology Department, N.C Medical College and Hospital
Dr. Ankita Saroha* Tutor, Microbiology Department, BPS GMC, Sonepat

DOI:

https://doi.org/10.36676/jrps.v15.i2.1592

Keywords:

Cancer, Treatment, Targeting, Immune System

Abstract

A revolutionary new method for treating cancer, immunotherapy uses the immune system to specifically target and kill tumor cells. Recent developments in immunotherapy and its function in cancer treatment are summarized in this article. This article provides a comprehensive overview of immunotherapeutic techniques, including bispecific antibodies, cancer vaccines, immune checkpoint combo therapy, checkpoint inhibitors, TIL therapy, CAR T-cell therapy, and cancer vaccines. It also discusses the mechanisms of action of these strategies and their clinical uses. Immunotherapy has shown tremendous promise in the treatment of many malignancies, according to recent important advances in the area as well as clinical data and case studies.

References

Havel, J. J., Chowell, D., & Chan, T. A. (2019). The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nature Reviews Cancer, 19(3), 133-150. DOI: https://doi.org/10.1038/s41568-019-0116-x

Maude, S. L., & Laetsch, T. W. (2020). Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. New England Journal of Medicine, 378(5), 439-448. DOI: https://doi.org/10.1056/NEJMoa1709866

Rosenberg, S. A., & Restifo, N. P. (2015). Adoptive cell transfer as personalized immunotherapy for human cancer. Science, 348(6230), 62-68. DOI: https://doi.org/10.1126/science.aaa4967

Sahin, U., Derhovanessian, E., Miller, M., Kloke, B. P., & Simon, P. (2017). Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature, 547(7662), 222-226.

Hellmann, M. D., & Paz-Ares, L. (2018). Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer. New England Journal of Medicine, 379(22), 2108-2121.

Lumley, M. A., Osoba, D., & Stockler, M. R. (2019). Quality of life impact of sipuleucel-T for asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer. Journal of Clinical Oncology, 37(14), 1192-1201.

Sharma, P., & Allison, J. P. (2015). The future of immune checkpoint therapy. Science, 348(6230), 56-61. DOI: https://doi.org/10.1126/science.aaa8172

June, C. H., & Sadelain, M. (2018). Chimeric Antigen Receptor Therapy. New England Journal of Medicine, 379(1), 64-73. DOI: https://doi.org/10.1056/NEJMra1706169

Ott, P. A., Hu, Z., & Keskin, D. B. (2017). An immunogenic personal neoantigen vaccine for patients with melanoma. Nature, 547(7662), 217-221. DOI: https://doi.org/10.1038/nature22991

Hellmann, M. D., Ciuleanu, T. E., & Pluzanski, A. (2018). Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. New England Journal of Medicine, 378(22), 2093-2104. DOI: https://doi.org/10.1056/NEJMoa1801946

Baeza, A. (2020). Tumor Targeted Nanocarriers for Immunotherapy. Molecules, 25(7), 1508. https://doi.org/10.3390/molecules25071508 DOI: https://doi.org/10.3390/molecules25071508

Conniot, J., Silva, J. M., Fernandes, J. G., Silva, L. C., Gaspar, R., Brocchini, S., Florindo, H. F., & Barata, T. S. (2014). Cancer immunotherapy: Nanodelivery approaches for immune cell targeting and tracking. Frontiers in Chemistry, 2. https://doi.org/10.3389/fchem.2014.00105 DOI: https://doi.org/10.3389/fchem.2014.00105

Dhar, R., Seethy, A., Singh, S., Pethusamy, K., Srivastava, T., Talukdar, J., Rath, G., & Karmakar, S. (2021). Cancer immunotherapy: Recent advances and challenges. Journal of Cancer Research and Therapeutics, 17(4), 834. https://doi.org/10.4103/jcrt.JCRT_1241_20 DOI: https://doi.org/10.4103/jcrt.JCRT_1241_20

Dou, L., Meng, X., Yang, H., & Dong, H. (2021). Advances in technology and applications of nanoimmunotherapy for cancer. Biomarker Research, 9(1), 63. https://doi.org/10.1186/s40364-021-00321-9 DOI: https://doi.org/10.1186/s40364-021-00321-9

Kamta, J., Chaar, M., Ande, A., Altomare, D. A., & Ait-Oudhia, S. (2017). Advancing Cancer Therapy with Present and Emerging Immuno-Oncology Approaches. Frontiers in Oncology, 7. https://doi.org/10.3389/fonc.2017.00064 DOI: https://doi.org/10.3389/fonc.2017.00064

Kciuk, M., Yahya, E. B., Mohamed Ibrahim Mohamed, M., Rashid, S., Iqbal, M. O., Kontek, R., Abdulsamad, M. A., & Allaq, A. A. (2023). Recent Advances in Molecular Mechanisms of Cancer Immunotherapy. Cancers, 15(10), 2721. https://doi.org/10.3390/cancers15102721 DOI: https://doi.org/10.3390/cancers15102721

Liu, D., Che, X., Wang, X., Ma, C., & Wu, G. (2023). Tumor Vaccines: Unleashing the Power of the Immune System to Fight Cancer. Pharmaceuticals, 16(10), 1384. https://doi.org/10.3390/ph16101384 DOI: https://doi.org/10.3390/ph16101384

Liu, J., Zhang, R., & Xu, Z. P. (2019). Nanoparticle‐Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions. Small, 15(32), 1900262. https://doi.org/10.1002/smll.201900262 DOI: https://doi.org/10.1002/smll.201900262

Liu, M., & Guo, F. (2018). Recent updates on cancer immunotherapy. Precision Clinical Medicine, 1(2), 65–74. https://doi.org/10.1093/pcmedi/pby011 DOI: https://doi.org/10.1093/pcmedi/pby011

Mishra, A. K., Ali, A., Dutta, S., Banday, S., & Malonia, S. K. (2022). Emerging Trends in Immunotherapy for Cancer. Diseases, 10(3), 60. https://doi.org/10.3390/diseases10030060 DOI: https://doi.org/10.3390/diseases10030060

Peterson, C., Denlinger, N., & Yang, Y. (2022). Recent Advances and Challenges in Cancer Immunotherapy. Cancers, 14(16), 3972. https://doi.org/10.3390/cancers14163972 DOI: https://doi.org/10.3390/cancers14163972

Tang, T., Huang, X., Zhang, G., Hong, Z., Bai, X., & Liang, T. (2021). Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Signal Transduction and Targeted Therapy, 6(1), 72. https://doi.org/10.1038/s41392-020-00449-4 DOI: https://doi.org/10.1038/s41392-020-00449-4

Yu, L., Sun, M., Zhang, Q., Zhou, Q., & Wang, Y. (2022). Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy. Frontiers in Immunology, 13, 982026. https://doi.org/10.3389/fimmu.2022.982026 DOI: https://doi.org/10.3389/fimmu.2022.982026